Telpegfilgrastim
Chemotherapy-induced Neutropenia
Anhui Provincial Hospitalprotein_peptideActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Chemotherapy-induced Neutropenia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PEGFILGRASTIM BeyondSpring Pharmaceuticals Inc. | Phase 3 | BBB |
Inno-206 BeyondSpring Pharmaceuticals Inc. | Phase 3 | BB |
FILGRASTIM Ankara Etlik City Hospital | Phase 3 | BB |
EMPEGFILGRASTIM Biocad | Phase 3 | BB |
Docetaxel BeyondSpring Pharmaceuticals Inc. | Phase 3 | BB |
View all 25 →
Same molecule, other indications
Telpegfilgrastim is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →